. 2020 Jul 6;80(12):1235–1245. doi: 10.1007/s40265-020-01357-1

Table 3.

Efficacy of subcutaneous risankizumab in adults with moderate to severe plaque psoriasis at week 44 [16] or 52 [15, 17] (part B) in pivotal phase III trials

Trial	Treatment (no. of pts)	PASI (% pts)			sPGA (% pts)		DLQI 0 or 1 (% pts)	PSS 0 (% pts)
Trial	Treatment (no. of pts)	75	90^a	100	0	0 or 1^b	DLQI 0 or 1 (% pts)	PSS 0 (% pts)
UltIMMa-1 [15]	RIS (304)	92^††	82^††	56^††	58^††	86^††	75^††	57^††
	UST (100)	70	44	21	21	54	47	30
	PL → RIS (97)	93	78	55	55	91	62	51
UltIMMa-2 [15]	RIS (294)	92^†	81^††	60^††	60^††	83^††	71^††	54^††
	UST (99)	77	51	30	30	55	44	30
	PL → RIS (94)	93	85	67	67	87	68	48
IMMvent [16]	ADA ↕ RIS (53)	91^‡	66^‡	40^‡	40^‡	74^‡	66^‡
IMMvent [16]	ADA ↕ ADA (56)	46	21	7	7	34	29
IMMhance [17]	RIS ↕ RIS (111)	93*	86*	64*	65^c*	87*
IMMhance [17]	RIS ↕ PL (225)	72	52	30	30^c	61

ADA adalimumab, DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index, PASI x improvement of ≥ x% from baseline in PASI score, PL placebo, PSS Psoriasis Symptom Scale, pts patients, RIS risankizumab, sPGA static Physician’s Global Assessment, UST ustekinumab, → indicates switched, ↕ indicates re-randomized

^†p = 0.001, ^††p < 0.0001 vs UST; ^‡p < 0.0001 vs ADA ↕ ADA; *p < 0.001 vs RIS ↕ PL (all nominal except for sPGA 0 or 1)

^aPrimary endpoint in part B of IMMvent [16]

^bPrimary endpoint in part B of IMMhance [17]

^cValue estimated from a graph